Medline ® Abstract for Reference 158
of 'Chemotherapy hepatotoxicity and dose modification in patients with liver disease'
Etoposide-induced hepatic injury: a potential complication of high-dose therapy.
Johnson DH, Greco FA, Wolff SN
Cancer Treat Rep. 1983;67(11):1023.
Two cases of toxic hepatitis developing in patients receiving high-dose etoposide (VP-16-213) for refractory germinal neoplasms are described. Each patient received a total cumulative dose of at least 6800 mg/m2. Liver function abnormalities, including hyperbilirubinemia, elevated transaminases, and elevated alkaline phosphatase, became clinically apparent approximately 3 weeks following the last dose of VP-16-213. These abnormalities resolved spontaneously without sequelae over 12 weeks. High-dose VP-16-213 may be associated with hepatic injury.